港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

维立志博-B

67.100

+32.10091.71%

成交量：3,311.83万

成交额：23.49亿

市值：129.50亿

市盈率：-38.90

高：79.600

开：72.400

低：67.100

收：35.000

数据加载中...

总览公司新闻公告

IPO周报｜本周1只新股申购，创业板迎电子树脂头部供应商

维立志博上市聆讯获通过

微博财经-财道工作室

【新股IPO】南京维立志博生物科技股份有限公司通过港交所主板上市聆讯

维立志博累亏超7亿：百济神州今年终止协议，短期偿债压力偏大

港湾商业观察

维立志博累亏超7亿：百济神州今年终止协议，短期偿债压力偏大

IPO前夕股东折价“出逃”！百济神州“断供”后，维立志博“零收入”冲港｜创新药观察

维立志博二战港交所IPO：三年亏损近十亿短债压力增大

维立志博二战港交所：核心管线商业化前景或有限三年亏近十亿现金已无法覆盖短债

估值30亿元，维立志博二闯港交所，造血能力不足期内仅一名客户

维立志博继续冲刺「国内TCE领域第一股」，核心产品有望填补重大治疗缺口

据港交所文件，南京维立志博生物科技股份有限公司向港交所提交了上市申请，联席保荐人为摩根士丹利与中信证券。

南京维立志博生物科技股份有限公司药品申请临床试验默示许可获受理

新股消息维立志博、极智嘉等七家公司港股IPO备案申请材料获中国证监会接收

新股消息 | 维立志博、极智嘉等七家公司港股IPO备案申请材料获中国证监会接收

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/09887/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"维立志博-B","latestPrice":67.1,"timestamp":1753430887036,"preClose":35,"halted":0,"volume":33118341,"delay":0,"floatShares":148000000,"shares":193000000,"eps":-1.725,"marketStatus":"休市中","change":32.1,"latestTime":"07-25 16:08:07","open":72.4,"high":79.6,"low":67.1,"amount":2349489336,"amplitude":0.357143,"askPrice":67.4,"askSize":100,"bidPrice":67.1,"bidSize":700,"shortable":0,"etf":0,"ttmEps":-1.651777067,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":7,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":35,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":148000000,"roa":"--","roe":"--","lyrEps":-1.725,"shares":193000000,"dividePrice":0,"high":79.6,"amplitude":0.357143,"preClose":35,"low":67.1,"week52Low":67.1,"pbRate":"61.40","week52High":79.6,"institutionHeld":0,"latestPrice":67.1,"committee":0.75,"eps":-1.725,"divideRate":0,"volume":33118341,"delay":0,"ttmEps":-1.651777067,"open":72.4,"prevYearClose":35,"prevWeekClose":35,"prevMonthClose":35,"prevQuarterClose":35,"fiveDayClose":35,"twentyDayClose":35,"sixtyDayClose":35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2547035640","title":"IPO周报｜本周1只新股申购，创业板迎电子树脂头部供应商","url":"https://stock-news.laohu8.com/highlight/detail?id=2547035640","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547035640?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 08:00","pubTimestamp":1751241631,"startTime":"0","endTime":"0","summary":"本周新股申购迎来覆铜板领域电子树脂供应商的本土高新技术企业。同宇新材主营业务为电子树脂的研发、生产和销售，主要应用于覆铜板生产。据华金证券研报，同宇新材是领先的覆铜板领域电子树脂本土供应商，近年来产品销量在同行业内资企业中均名列前茅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630080256a4c52246&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630080256a4c52246&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0175","09887","02648","159982","IE0005HP3H50.USD","399300","BK0214","BK0185","BK0201","BK0028","000001.SH","603186","159915","BK0188","603345","399006","688519","601127","600183"],"gpt_icon":0},{"id":"2545630281","title":"维立志博上市聆讯获通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2545630281","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545630281?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 18:55","pubTimestamp":1750762500,"startTime":"0","endTime":"0","summary":"来源：@经济观察报微博公司动态6月23日，港交所披露，南京维立志博生物科技股份有限公司上市聆讯获通过，公司将登陆港交所主板上市，联席保荐人为摩根士丹利和中信证券。维立志博于2012年成立，是一家临床阶段生物科技公司，专注于肿瘤、自身免疫性疾病及其他重大疾病新疗法的发现、开发及商业化。目前，公司尚无产品获批进行商业销售，也未从产品销售中产生任何收入。在业绩记录期间，维立志博未实现盈利，存在经营亏损。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2025-06-24/doc-infcerue8890258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MUCmain","UCmain","CNHmain","CYB","09887","MCNHmain"],"gpt_icon":0},{"id":"2545466443","title":"【新股IPO】南京维立志博生物科技股份有限公司通过港交所主板上市聆讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2545466443","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545466443?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 23:03","pubTimestamp":1750690999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所6月23日披露，南京维立志博生物科技股份有限公司通过港交所主板上市聆讯，摩根士丹利、中信证券为联席保荐人。公司于2012年成立，是一家临床阶段生物科技公司，专注于中国及全球肿瘤、自身免疫性疾病及其他重大疾病新疗法的发现、开发及商业化。公司的管线包括14款候选药物，其中6款已进入临床阶段，包括1款核心产品及3款主要产品。公司现时并无产品获准进行商业销售，亦未自产品销售产生任何收入。","market":"other","thumbnail":"https://static.szfiu.com/news/20220324/MGRlNTRkNjg5NzY4YzMxZDdjZGQ5OGEzMzIxODkyNzUxMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MGRlNTRkNjg5NzY4YzMxZDdjZGQ5OGEzMzIxODkyNzUxMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960961","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159837","09887","HEXmain"],"gpt_icon":1},{"id":"2544184573","title":"维立志博累亏超7亿：百济神州今年终止协议，短期偿债压力偏大","url":"https://stock-news.laohu8.com/highlight/detail?id=2544184573","media":"港湾商业观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544184573?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 08:20","pubTimestamp":1750292443,"startTime":"0","endTime":"0","summary":"根据百济神州提供的终止通知所指，该协议其后已于2025年5月18日终止。百济神州并无披露亦无计划披露终止协议的原因。2现金流连年为负，短期偿债压力偏大从开支来看，研发成本无疑是最大支出。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619083409a7116e13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619083409a7116e13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK0239","688235","09887"],"gpt_icon":0},{"id":"2544138489","title":"维立志博累亏超7亿：百济神州今年终止协议，短期偿债压力偏大","url":"https://stock-news.laohu8.com/highlight/detail?id=2544138489","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544138489?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 08:20","pubTimestamp":1750292400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2025-06-19/doc-infaqerx4105959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU0588546209.SGD","BK4526","BK1588","BK4139","09887","BK1161","ONC","BK1500","06160","LU2328871848.SGD","LU1969619763.USD","688235","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2544594029","title":"IPO前夕股东折价“出逃”！百济神州“断供”后，维立志博“零收入”冲港｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2544594029","media":"华夏时报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544594029?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 14:34","pubTimestamp":1750228440,"startTime":"0","endTime":"0","summary":"除化疗外，全球范围内尚无专门用于治疗晚期肺外神经内分泌癌的获批药物。百济神州“断供”斩断唯一收入链与众多处于研发驱动期的创新药企相似，维立志博尚未实现产品商业化落地，持续投入的高额研发成本正不断消耗资金储备。2022年至2025年一季度，维立志博的客户名单上仅有百济神州这根“独苗”。至此，维立志博失去了唯一的收入来源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-06-18/doc-infannhi5773839.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-06-18/doc-infannhi5773839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09887","BK1583","159992","BK4139","BK4526","06160","BK1161","06978","BK1588","BK1500","BK0239","ONC","BK1574","LU0307460666.USD","LU2328871848.SGD","LU0588546209.SGD","LU1969619763.USD","688235"],"gpt_icon":0},{"id":"2542376888","title":"维立志博二战港交所IPO：三年亏损近十亿 短债压力增大","url":"https://stock-news.laohu8.com/highlight/detail?id=2542376888","media":"电鳗快报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542376888?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 11:23","pubTimestamp":1749612180,"startTime":"0","endTime":"0","summary":"《电鳗财经》电鳗号/文维立志博二次叩响港交所大门，但公司三年累计亏损近十亿，这场IPO更像一场与时间的赛跑。相关媒体报道显示，从2022年至2024年，维立志博亏损额分别达2.81亿元、3.62亿和3.01亿元，三年亏近十亿元;报告期内，维立志博的研发开支分别约为1.85亿元、2.31亿元和1.86亿元。截至2025年3月，该公司现金及现金等价物为4.31亿元，流动负债总额为4.62亿元，现金已无法覆盖短债。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-06-11/doc-inezskcq8194097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HEXmain","09887"],"gpt_icon":0},{"id":"2542313797","title":"维立志博二战港交所：核心管线商业化前景或有限 三年亏近十亿现金已无法覆盖短债","url":"https://stock-news.laohu8.com/highlight/detail?id=2542313797","media":"乐居财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542313797?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 17:50","pubTimestamp":1749549000,"startTime":"0","endTime":"0","summary":"据港交所资料显示，2024年11月维立志博首次向港交所递表，但以招股书失效告终。　　维立志博于2021年12月就LBL-007与百济神州订立授权及合作协议，但该协议已于2025年5月18日终止，协议终止原因并未披露。截至2025年3月，公司现金及现金等价物为4.31亿元，流动负债总额为4.62亿元，现金已无法覆盖短债。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/estate/integration/2025-06-10/doc-inezqwaa3367189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09887","HEXmain"],"gpt_icon":0},{"id":"2542896733","title":"估值30亿元，维立志博二闯港交所，造血能力不足期内仅一名客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2542896733","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542896733?lang=zh_cn&edition=fundamental","pubTime":"2025-06-09 19:18","pubTimestamp":1749467925,"startTime":"0","endTime":"0","summary":"在TCE赛道，维立志博是重要的竞争者之一。维立志博表示，研发方面预期将继续产生有关临床试验及临床前研究的重大开支。截至2025年3月31日，维立志博持有的现金及现金等价物为4.31亿元，存在计息银行借款2.55亿元，融资已迫在眉睫。2024年12月8日，维立志博首次向港交所递表。2024年9月至11月，维立志博发生了股权转让，且截至2024年11月27日，股份转让皆已完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1749465023104002184","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["09887","BK4080","ADC","BK4231"],"gpt_icon":0},{"id":"1198711699","title":"维立志博继续冲刺「国内TCE领域第一股」，核心产品有望填补重大治疗缺口","url":"https://stock-news.laohu8.com/highlight/detail?id=1198711699","media":"IPO早知道","labels":["productRelease","analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198711699?lang=zh_cn&edition=fundamental","pubTime":"2025-06-05 14:57","pubTimestamp":1749106654,"startTime":"0","endTime":"0","summary":"维立志博成立于2012年，是一家临床阶段生物科技公司，专注于发现、开发及商业化用于治疗中国及全球肿瘤、自身免疫性疾病及其他重大疾病的创新疗法。值得一提的是，维立志博基于LeadsBody专有技术平台，已构建覆盖血液瘤、实体瘤及自免三大疾病领域的TCE产品矩阵。来源：维立志博招股书其中，维立志博有6款产品已进入临床阶段，包括1款核心产品及3款主要产品。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://mp.weixin.qq.com/s/m7aP1OXztSgumsWXBZRe_w","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,analysis","news_rank":0,"length":0,"strategy_id":0,"source":"ipozaozhidao","symbols":["09887"],"gpt_icon":0},{"id":"2540050167","title":"据港交所文件，南京维立志博生物科技股份有限公司向港交所提交了上市申请，联席保荐人为摩根士丹利与中信证券。","url":"https://stock-news.laohu8.com/highlight/detail?id=2540050167","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540050167?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 18:59","pubTimestamp":1749034771,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU1989772923.USD","BK4581","LU0405327148.USD","BK1516","LU1074936037.SGD","LU1363072403.SGD","LU1997245094.SGD","BK4585","LU1720051108.HKD","LU1732800096.USD","LU0267386448.USD","BK0028","IE00BZ1G4Q59.USD","LU2289578879.USD","09887","BK4516","BK0012","LU1997245177.USD","LU1720050803.USD","159837","BK4127","BK4534","LU0320765646.SGD","LU1064131003.USD","LU1548497426.USD","BK0188","LU1668664300.SGD","LU2347655156.SGD","LU0795875169.SGD","LU0158827948.USD","06030","LU0912757837.SGD","LU1794554557.SGD","LU0314104364.USD","LU0106831901.USD","LU0405327494.USD","LU1064130708.USD","LU0158827781.USD","LU2111349929.HKD","LU0225283273.USD","BK0183","LU0234570918.USD","BK1147","BK4504","BK4588","LU1328615791.USD","600030","LU1989772840.SGD","LU0106261372.USD","IE00BKVL7J92.USD","BK0276"],"gpt_icon":0},{"id":"2528823737","title":"南京维立志博生物科技股份有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2528823737","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528823737?lang=zh_cn&edition=fundamental","pubTime":"2025-04-17 12:16","pubTimestamp":1744863388,"startTime":"0","endTime":"0","summary":"4月17日，据CDE官网消息，南京维立志博生物科技股份有限公司联合申请药品“注射用LBL-024”，获得临床试验默示许可，受理号CXSL2500112。南京维立志博生物科技股份有限公司，成立于2012年，位于南京市，是一家以从事专业技术服务业为主的企业。通过天眼查大数据分析，南京维立志博生物科技股份有限公司共对外投资了3家企业，参与招投标项目2次，知识产权方面有商标信息40条，专利信息23条，此外企业还拥有行政许可27个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/17121649612041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1583","BK1141","159837","BK1576","09887"],"gpt_icon":0},{"id":"2509717897","title":"新股消息   维立志博、极智嘉等七家公司港股IPO备案申请材料获中国证监会接收","url":"https://stock-news.laohu8.com/highlight/detail?id=2509717897","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509717897?lang=zh_cn&edition=fundamental","pubTime":"2025-02-07 19:59","pubTimestamp":1738929550,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/JNQOQPKH0519QIKK.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/JNQOQPKH0519QIKK.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["09887"],"gpt_icon":0},{"id":"2509923714","title":"新股消息 | 维立志博、极智嘉等七家公司港股IPO备案申请材料获中国证监会接收","url":"https://stock-news.laohu8.com/highlight/detail?id=2509923714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509923714?lang=zh_cn&edition=fundamental","pubTime":"2025-02-07 19:43","pubTimestamp":1738928598,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月7日，中国证监会发布《境内企业境外发行证券和上市备案情况表(首次公开发行及全流通)(截至2025年2月7日)》。本周(2月3日-2月7日)，乐欣户外、维立志博、BUTONG GROUP（不同集团）、乾元微珂、极智嘉、海西新药、劲方医药港股IPO备案申请材料获中国证监会接收。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","YANG","HSCEI","HSTECH"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":54,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2025-07-25","current":-39.760016,"percent":1,"low":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"high":-39.760016,"avg":-39.760016,"sd":0,"marketCap":12652000240},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240}],"updateTime":1753571613298}}}